Leerink Partnrs Has Pessimistic Outlook of REGN Q1 Earnings

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) – Equities research analysts at Leerink Partnrs cut their Q1 2025 EPS estimates for shares of Regeneron Pharmaceuticals in a research note issued to investors on Tuesday, April 1st. Leerink Partnrs analyst D. Risinger now forecasts that the biopharmaceutical company will earn $7.07 per share for the quarter, down from their prior estimate of $7.56. Leerink Partnrs currently has a “Strong-Buy” rating on the stock. The consensus estimate for Regeneron Pharmaceuticals’ current full-year earnings is $35.92 per share. Leerink Partnrs also issued estimates for Regeneron Pharmaceuticals’ Q2 2025 earnings at $8.22 EPS, Q3 2025 earnings at $9.62 EPS, Q4 2025 earnings at $9.56 EPS, FY2025 earnings at $34.47 EPS and FY2026 earnings at $35.16 EPS.

A number of other analysts have also recently weighed in on the stock. Sanford C. Bernstein dropped their target price on shares of Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an “outperform” rating on the stock in a report on Tuesday, January 7th. Canaccord Genuity Group assumed coverage on shares of Regeneron Pharmaceuticals in a research note on Tuesday, December 17th. They set a “hold” rating and a $165.00 price objective on the stock. Bank of America reissued an “underperform” rating and issued a $565.00 target price on shares of Regeneron Pharmaceuticals in a report on Tuesday, December 10th. Truist Financial lowered their target price on Regeneron Pharmaceuticals from $1,126.00 to $1,004.00 and set a “buy” rating for the company in a report on Wednesday, January 8th. Finally, Leerink Partners upgraded Regeneron Pharmaceuticals from a “market perform” rating to an “outperform” rating and increased their price target for the stock from $762.00 to $834.00 in a research report on Wednesday, February 5th. One investment analyst has rated the stock with a sell rating, six have given a hold rating, seventeen have issued a buy rating and two have given a strong buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $966.88.

Regeneron Pharmaceuticals Stock Performance

REGN stock opened at $625.60 on Thursday. The stock’s 50 day simple moving average is $680.43 and its 200 day simple moving average is $786.93. Regeneron Pharmaceuticals has a 12-month low of $605.56 and a 12-month high of $1,211.20. The firm has a market cap of $68.39 billion, a P/E ratio of 16.34, a P/E/G ratio of 2.34 and a beta of 0.27. The company has a current ratio of 4.73, a quick ratio of 3.95 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share (EPS) for the quarter, beating the consensus estimate of $11.21 by $0.86. The firm had revenue of $3.79 billion for the quarter, compared to analysts’ expectations of $3.76 billion. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. Regeneron Pharmaceuticals’s revenue for the quarter was up 10.3% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $11.86 earnings per share.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of REGN. State Street Corp grew its stake in shares of Regeneron Pharmaceuticals by 1.3% in the 3rd quarter. State Street Corp now owns 4,902,404 shares of the biopharmaceutical company’s stock worth $5,153,603,000 after purchasing an additional 61,277 shares during the last quarter. Capital International Investors boosted its holdings in Regeneron Pharmaceuticals by 41.6% during the fourth quarter. Capital International Investors now owns 4,736,929 shares of the biopharmaceutical company’s stock worth $3,373,859,000 after buying an additional 1,390,534 shares in the last quarter. Geode Capital Management LLC grew its position in Regeneron Pharmaceuticals by 6.8% in the fourth quarter. Geode Capital Management LLC now owns 2,427,630 shares of the biopharmaceutical company’s stock worth $1,726,940,000 after buying an additional 155,369 shares during the last quarter. Dodge & Cox increased its holdings in shares of Regeneron Pharmaceuticals by 0.4% in the fourth quarter. Dodge & Cox now owns 2,321,316 shares of the biopharmaceutical company’s stock valued at $1,653,543,000 after buying an additional 9,381 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD lifted its position in shares of Regeneron Pharmaceuticals by 63.5% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 2,085,447 shares of the biopharmaceutical company’s stock valued at $1,485,527,000 after acquiring an additional 810,144 shares during the last quarter. 83.31% of the stock is owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Thursday, March 20th. Investors of record on Thursday, February 20th were paid a dividend of $0.88 per share. The ex-dividend date of this dividend was Thursday, February 20th. This represents a $3.52 annualized dividend and a yield of 0.56%. Regeneron Pharmaceuticals’s dividend payout ratio is currently 2.30%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.